# Wockhardt share price today (Wockhardt Ltd, NSE: WOCKPHARMA)

> Wockhardt share price today: ₹1,899.00 at the NSE close on 4 November 2026, up 42.0% in a year. Wockhardt (NSE: WOCKPHARMA) is worth ₹30,862 crore, trades at a P/E of 77.4 and has closed between ₹1,176.20 and ₹2,266.40 over the past 52 weeks. > Wockhardt Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 32% of past readings. WOCKPHARMA · Pharma - Formulators · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/wockhardt-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹1,899.00 (+42.0% in a year)
- P/E: 77.4× (lower than 68% of the last 11 years)
- Revenue (Jun 2026): ₹929 Cr (+25.9% on a year ago)
- Profit (Jun 2026): ₹107 Cr
- Operating margin: 21.0% (+11.0 points on a year ago)
- ROCE: 8%, FY26
- ROIC: 7.6%, against a 12.0% cost of capital: −4.4 points
- Profit that came in as cash: 5%, last 3 years

The main question: profits are rising, but only 5% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Wockhardt share price today? Wockhardt Ltd's share price was ₹1,899.00 at the close on 4 November 2026. It has been rising for 24 weeks. That is 6.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,176 and ₹2,266, and at that close it sat 66% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 11 weeks in a row. Over the last 11 years the share price moved +112% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Wockhardt this quarter? Three changes stood out: operating margin up 11 points on a year earlier, profit up on a year earlier for 4 quarters in a row and number of shareholders up 25% in a year. 1. Operating margin up 11 points on a year earlier 21% in the June 2026 quarter, from 10%. 2. Profit up on a year earlier for 4 quarters in a row In the June 2026 quarter profit was ₹107 crore, +199.1% on a year earlier. 3. Number of shareholders up 25% in a year 1,73,116 shareholders in the September 2026 quarter, against 1,37,946 a year earlier. ## What are Wockhardt's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Wockhardt reported revenue of ₹929 crore, up 25.9% from ₹738 crore a year earlier, and a profit of ₹107 crore, against a loss of ₹108 crore a year earlier. ### Wockhardt results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹929 crore | ₹738 crore | +25.9% |
| Profit | ₹107 crore | loss of ₹108 crore | n/a |
| Earnings per share | ₹6.52 | ₹−5.54 | n/a |
| Operating margin | 21.0% | 10.0% | +11.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 4 June 2026, about January to March 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Wockhardt share price history? Wockhardt closed at ₹1,899.00 on 4 November 2026, up 42.0% from ₹1,337.70 a year earlier (7 November 2025) and up 367.7% over five years. Its highest weekly close since March 2016 was ₹2,266.40 on 25 September 2026. ### Wockhardt share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹1,896.10 | +0.2% |
| 1 month ago · 1 Oct 2026 | ₹2,086.50 | −9.0% |
| 6 months ago · 8 May 2026 | ₹1,606.50 | +18.2% |
| 1 year ago · 7 Nov 2025 | ₹1,337.70 | +42.0% |
| 3 years ago · 3 Nov 2023 | ₹238.70 | +695.6% |
| 5 years ago · 4 Nov 2021 | ₹406.02 | +367.7% |
| 10 years ago · 4 Nov 2016 | ₹735.20 | +158.3% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹895.87 | +112.0% |
| Highest weekly close since March 2016, also the 52-week high · 25 Sep 2026 | ₹2,266.40 | −16.2% |
| Lowest weekly close since March 2016 · 31 Mar 2023 | ₹153.90 | +1,133.9% |
| 52-week low (weekly close) · 20 Mar 2026 | ₹1,176.20 | +61.5% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Wockhardt? 4 Nov 2026: Wockhardt closed at ₹1,899.00, up 0.2% on the week and down 9.0% on the month. Results for April to June 2026: Revenue up 25.9% on a year earlier. ### Earlier

- Our read, 14 Jun 2026: A decade-long R&D bet on novel antibiotics is finally delivering, Zaynic FDA approval creates a $1.5-2B peak sales path, while FY26 profitability and 19% operating margin prove the base business has structurally recovered. - 4 Jun 2026: Wockhardt held its results call for January to March 2026. Management guided: Zaynic launch in India within current fiscal year. ### Our read of the business

FY26 closes at profit ₹199 Cr (first profitable full year since FY22) on revenue ₹3,373 Cr and operating profit 19%, a 1,300 basis points margin recovery driven by product mix shift away from generics toward specialty biosimilars and novel antibiotics now at 23% of business.,Zaynic (WCK-5222) received FDA approval June 2026, the first Indian company-discovered drug approved by US FDA, with Phase 3 showing 96.8% composite cure rate vs Meropenem and peak global revenue guidance of $1.5-2 billion; the US commercial launch is underway with a 12-18 month slow ramp to breakeven.,Second growth leg is diabetes biosimilars (27% FY26 growth, doubling capacity in 12-15 months) in a market with only 6-7 competitors, with the UK business at 39% of revenue and 13% growth providing stable earnings base while NCE revenues ramp. Latest quarter: Best quarter on record, operating margin 23%, profit ₹164 Cr, revenue +29.9% on a year earlier closes FY26 as first profitable year since FY22. (Our read after the latest results, written 14 June 2026.)

## What dividend does Wockhardt pay? Wockhardt has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Wockhardt Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 2 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Wockhardt management say on the latest results call? On the call for January to March 2026, held on 4 June 2026, Wockhardt's management guided: Zaynic launch in India within current fiscal year. > “For many years, investors asked us when the investment in research, biotech, and innovation would begin to translate into growth. We believe that moment has arrived”
> Dr. Murtaza Khorakiwala, Managing Director, on the call for January to March 2026

### What management guided

- European regulatory approval for Zaynic planned end-of-year. - Novel antibiotic segment operating breakeven expected 12-18 months post-launch. - Zaynic peak global annual revenue $1.5-2 billion. - Biosimilar business to double size within 24-36 months. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4311/Conference Call/CC-Jun26.pdf). (From the call for January to March 2026, 4 June 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What is the future of Wockhardt? What is changing in the business? What is changing at Wockhardt, from the latest results and calls: zaynic (wck-5222), fda approved, us commercial launch underway, biosimilar platform, 27% growth + capacity doubling and miqnaf + emrok, novel antibiotic base revenue. - Zaynic (WCK-5222), FDA Approved, US Commercial Launch Underway. FDA approval received; US commercial launch with experienced team (ex-Shionogi CCO) underway; 12-18 month hockey-stick ramp to segment breakeven; peak global revenue $1.5-2B guided. ⚠ estimate
- Biosimilar Platform, 27% Growth + Capacity Doubling. Biosimilar business grew 27% FY26; insulin 2x, glargine 1.5x capacity; plan to double business in 24-36 months; 6-7 competitors vs 15-20 in MoAbs creates pricing headroom. ⚠ estimate
- Miqnaf + EMROK, Novel Antibiotic Base Revenue. Miqnaf: first new macrolide in 35 years, launched May 2025; EMROK: 100K patients, ~10% market share, two validated specialty commercial channels. ⚠ estimate
- UK + Emerging Markets Core Business Stability. UK 39% of revenue, 13% growth, top-5 market position; EM 28% of revenue, 45% on a year earlier growth via strategic partnerships in FY26. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the latest results, written 14 June 2026.)

## What could change the Wockhardt story? What are the risks? Cash conversion cycle expanded 108 days from FY22 to FY26; primary driver is payables compression (from 265 to 182 days); inventory days also rising to 286 days, signals capacity build for biosimilar ramp. ### The main risks

- Working capital bloating, CCC expanded from 60 to 168 days: Cash conversion cycle expanded 108 days from FY22 to FY26; primary driver is payables compression (from 265 to 182 days); inventory days also rising to 286 days, signals capacity build for biosimilar ramp. ✓ fact
- Miqnaf and EMROK specialist channel validation at scale: Wockhardt is transitioning from generics distribution to specialist antibiotic commercialization, EMROK at 10% market share is proof of concept, but Miqnaf + Zaynic parallel launches test whether the organization can execute two specialist launches simultaneously. ✓ fact

(Our read after the latest results, written 14 June 2026.)

## What to watch in Wockhardt's next results? When Wockhardt reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Zaynic US commercial launch execution clarity: leadership team staffing velocity versus plan, early hospital system partnership announcements, initial formulary coverage placements by academic medical centers - roadmap to 12-18 month segment breakeven requires visible initial adoption signals. - What to check (from the call)
- Zaynic US commercial launch execution clarity: leadership team staffing velocity versus plan, early hospital system partnership announcements, initial formulary coverage placements by academic medical centers - roadmap to 12-18 month segment breakeven requires visible initial adoption signals. - European regulatory approval decision for Zaynic: management committed to end-of-year timing; approval on schedule critical for EU market access, manufacturing supply chain planning, and India/EM launch momentum given parallel launch strategy dependency. - Biosimilar capacity expansion execution: management committed 12-15 month timeline for insulin/glargine production doubling; watch for capital spending spend pace, manufacturing scale-up outcomes, and inventory builds supporting double business in 24-36 months growth trajectory. - Povisque DCGI registration filing submission: management stated 2-3 month timeframe; filing completion signals execution discipline on NCE pathway post-Zaynic and provides clarity on two-molecule early commercial sequencing. ## Which stock lists is Wockhardt on? Wockhardt is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 271](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 30860.87265267477](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Wockhardt profitable? Wockhardt Ltd earned ₹107 Cr of net profit in the Jun 2026 quarter. Full-year FY26 profit was ₹199 Cr. Over 10 years profit has grown −2.3% a year on average. That is 11.5% of the quarter's revenue. The same quarter a year earlier lost ₹108 Cr. 7 of the last 12 reported quarters were loss-making. ## How much revenue does Wockhardt make, and is it growing? Wockhardt Ltd reported ₹929 Cr of revenue in the Jun 2026 quarter, +25.9% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown −2.7% a year on average. The last full year, FY26, came in at ₹3,373 Cr. Why this happened. Zaynic received FDA approval, first Indian company-discovered drug approved by US FDA, per June 2026 concall (C045). Phase 3 showed 96.8% composite cure rate and 90% micro-cure vs Meropenem (C056). US commercial team is in place: CCO from Shionogi Fetroja launch, CMO from Boston hospital system, 3PL distribution partner (C055). Focus on academic medical centers with high-resistance Gram-negative patient populations. US adoption trajectory: 12-18 month slow ramp as infectious disease specialists learn the molecule, then material acceleration (C057). UK NHS subscription model (up to GBP 20M/year for 3 years independent of volume) de-risks revenue during ramp (C052). European regulatory…

The last four reported quarters add to ₹3,564 Cr. FY26 revenue was ₹3,373 Cr, +12.0% on the year before. Recent pace: the last four quarters grew +18.9% on average, against −2.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +18.4%, against +11.0% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Wockhardt keep? Wockhardt Ltd's operating margin was 21.0% in the Jun 2026 quarter, 11.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between −2.3% and 21.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +10.9 percentage points on the year while gross margin changed +1.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Wockhardt's profit turning into cash? Over the last 3 years, 5% of Wockhardt Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹390 Cr of operating cash against ₹199 Cr of profit. After ₹628 Cr of spending on assets, free cash was −₹238 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 5% of profit came in as cash: the cash cycle got 11 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 11 days longer. The next section looks at where the cash is stuck. ## Where does Wockhardt's cash go? Wockhardt Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 168 days in FY26, up from 157 days in FY21. It spent ₹1,256 Cr on assets over the last 3 years. Customers take 64 days to pay, and stock sits for 286 days on average. At FY26 sales of ₹3,373 Cr, each day of that cycle ties up about ₹9.2 Cr, so roughly ₹1,553 Cr is tied up in the business at any time. FY26: customers took 64 days to pay and stock sat for 286 days, about 9.4 months of sales sitting as stock, for a full cycle of 168 days, longer than FY21's 157. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 286 days. Customers pay about 64 days after that. Suppliers are paid at 182 days. Together that makes the 168-day cycle. Spending on assets: ₹1,256 Cr over the last 3 years, against ₹667 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹2,379 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Wockhardt's P/E ratio, and how does it compare with its own history? Wockhardt Ltd's P/E is 77.4×, near the low end of its own history: it has been lower only 32% of the time. Its usual P/E (the middle reading) is 90.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹25.17. Where the price move came from: over 10 years the price moved +10.0% a year; about +12.6% a year came from earnings growth and about −2.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Wockhardt business getting better or worse? Wockhardt Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## What is the Wockhardt story, and has it been checked? Wockhardt Ltd's story is not scored yet against the checks our research set on 14 June 2026. Where it sits in its own cycle: EARLY TURNAROUND. Our read, 14 June 2026. A decade-long R&D bet on novel antibiotics is finally delivering, Zaynic FDA approval creates a $1.5-2B peak sales path, while FY26 profitability and 19% EBITDA margin prove the base business has structurally recovered. From the numbers. FY26 EPS delivery (TTM INR 13.11) is starting to close the gap. At the 67th…

From the price. Price stage 2, week 24, above its 200-day line, relative strength falling. From the research. A decade-long R&D bet on novel antibiotics is finally delivering, Zaynic FDA approval creates a $1.5-2B peak sales path, while FY26 profitability and 19% EBITDA margin prove the base business has structurally recovered. Where they disagree. FY26 EPS delivery (TTM INR 13.11) is starting to close the gap. The decomposition remains PRICE DRIVEN, the market's anticipation of Zaynic commercialization revenue ran ahead of actual delivery. FII stake rose from 4.18% (Dec 2023) to 7.09% (Mar 2026); DII from 0.3% to 10.96%, institutional discovery is deepening post-FDA approval. The operating cycle is MID EXPANSION with OPM at the 98th percentile of its own 10Y range (23.3% vs trough -93.1%), current…

What is proven. A decade-long R&D bet on novel antibiotics is finally delivering, Zaynic FDA approval creates a $1.5-2B peak sales path, while FY26 profitability and 19% EBITDA margin prove the base business has structurally recovered. What is not proven yet. The test written in advance. Zaynic US commercial execution, 12-18 month hockey-stick gap. Measured by: Zaynic US commercial execution, 12-18 month hockey-stick gap by the next result. The test written in advance. The test written in advance. Working capital bloating, CCC expanded from 60 to 168 days. Measured by: Working capital bloating, CCC expanded from 60 to 168 days CCC normalizing below 120 days; payable days recovering toward 220+; inventory days stabilizing by the next result. Lever 12 · New product launch: building. FDA approval received; US commercial launch with experienced team (ex-Shionogi CCO) underway; 12-18 month hockey-stick ramp to segment breakeven; peak global revenue $1.5-2B guided. What proves it keeps working: Zaynic (WCK-5222), FDA Approved, US Commercial Launch Underway. It stops working if Quarterly Zaynic US revenue; hospital system formulary placement announcements; academic medical center adoption press releases. Lever 5 · Regulatory approval: building. Biosimilar business grew 27% FY26; insulin 2x, glargine 1.5x capacity; plan to double business in 24-36 months; 6-7 competitors vs 15-20 in MoAbs creates pricing headroom. What proves it keeps working: Biosimilar Platform, 27% Growth + Capacity Doubling. It stops working if Quarterly Zaynic US revenue; hospital system formulary placement announcements; academic medical center adoption press releases. Sources: our stock research file (14 June 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## How much does Wockhardt earn on its capital? Wockhardt Ltd earned a ROCE of 8% in FY26. That is up from a low of −3% in FY21. Its return on capital used (ROIC) is 4.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 5.9% net margin and 0.39× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 5.9% net margin × 0.39× asset turnover × 1.74× leverage (assets divided by equity) ≈ 4.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 7.6% − 12.0% = −4.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 7.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 6.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Wockhardt have too much debt? Wockhardt Ltd has total debt of ₹2,233 Cr against shareholder equity of ₹5,281 Cr as of Jun 2026, so its debt is 0.42× its equity. Year by year, that ratio went from 0.52 in FY22 to 0.42 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Wockhardt shareholding pattern? Domestic institutions raised their stake in Wockhardt Ltd by 3.9 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.0% of the company. Promoters moved −2.7 points over the same period, to 49.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +3.9 points over 8 quarters, to 9.0%; Promoters: −2.7 points over 8 quarters, to 49.3%; Foreign institutions: +0.3 points over 8 quarters, to 7.0%. Why the owners changed: domestic institutions drove it (+3.9 points), with the other side taken by promoters (−2.7 points). They raised their stake step by step. ## How far is Wockhardt from balance-sheet trouble? For Wockhardt Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. Why this happened. Biosimilar/biotech business grew 27% in FY26 supported by scaled manufacturing: human insulin output 2x higher, glargine production 1.5x higher (C048). Market opportunity: diabetes biosimilar market valued Rs 6-7B in India and EM with only 6-7 competitive players (C060). Production capacity to double in 12-15 months to support doubling the business in 24-36 months (C061). Pipeline depth: 5 molecules in late-stage development (Aspart, RN37D, Degludec, Degludec Aspart, Semaglutide) after two-year development horizon (C062). Novo Nordisk discontinuing disposable pens creates supply gap opportunity in EM. Povisque novel antibiotic DCGI filing planned within 2-3 months per June 2026 call (C063). ## How does Wockhardt rank in its industry? 52.9 out of 100, rank 20 of 44 in Pharma - Formulators, with 71% of the evidence available. Wockhardt Ltd scores 52.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 20. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 24.6 + 8.7 + 9 + 10.6 = 52.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Wockhardt compared with? Wockhardt ranks 20 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 52.9 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.0/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18 + 11 + 12.3 = 71.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.5/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.5 + 9.1 + 18.6 = 70.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.4 + 11.2 + 8.6 = 69.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 7.1 + 10.5 = 69 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 20.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 20.4 + 16.1 + 2 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 8. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Most evidence points up · 74% evidence 65.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 18.3/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 18.3 + 6.3 + 11.9 = 65.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.7 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.3 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative
16. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
17. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.0 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. Wockhardt Ltd this page WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.6/35 · Revenue 18.4% · Profit 100% · Operating margin change 11 points · 65% evidence Capital efficiency 8.7/25 · ROCE 7.5% · Operating margin 21% · 100% evidence Valuation 9.0/20 · P/E 77.5× · PEG n/a · 15% evidence Relative strength 10.6/20 · Lead over its industry -1.5% · Lead over NIFTY 500 21.3% · 1 year 48% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24.6 + 8.7 + 9 + 10.6 = 52.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 47.9 out of 100 Growth Capital Valuation Relative
24. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.6 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 45.9 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.4 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 40.7 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.3 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.4 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 33.6 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Wockhardt in size? Wockhardt is the 16th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Ajanta Pharma, J B Chemicals & Pharmaceuticals and Emcure Pharmaceuticals. Just below it: Rubicon Research, Caplin Point Laboratories and ERIS Lifesciences. ### Pharma - Formulators companies close in size

1. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) ₹43,846 crore
2. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) ₹38,677 crore
3. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) ₹35,510 crore
4. Wockhardt Ltd ₹30,895 crore
5. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) ₹26,660 crore
6. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) ₹17,677 crore
7. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ₹16,044 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Star Health & Allied Insurance Company Ltd](https://www.sectoralpha.in/stocks/star-health-allied-insurance-company-ltd) ₹31,221 crore · Finance - Non Life Insurance
2. [United Breweries Ltd](https://www.sectoralpha.in/stocks/united-breweries-ltd) ₹31,208 crore · Alcoholic Beverages
3. Wockhardt Ltd ₹30,895 crore
4. [Dr Lal Pathlabs Ltd](https://www.sectoralpha.in/stocks/dr-lal-pathlabs-ltd) ₹30,674 crore · Diagnostics
5. [Hexaware Technologies Ltd](https://www.sectoralpha.in/stocks/hexaware-technologies-ltd) ₹30,661 crore · IT - Software

## What else do people ask about Wockhardt? ### What is Wockhardt's share price today? Wockhardt Ltd's share price is ₹1,899.00, +42.0% over the past year. The whole company is worth ₹30,862 Cr on the market. In the last 52 weeks it traded between ₹1,176 to ₹2,266; today it is 66% of the way up from the low, 6.4% above its 200-day average (as of 4 November 2026). ### What were Wockhardt's latest quarterly results? Wockhardt Ltd reported revenue of ₹929 Cr and net profit of ₹107 Cr for the Jun 2026 quarter. Earnings per share were ₹6.52. The operating margin was 21.0%, 11.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Wockhardt's market cap? Wockhardt Ltd's market capitalisation is ₹30,862 Cr at a share price of ₹1,899.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Wockhardt performing? Wockhardt Ltd's share price has been rising for 24 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 11 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Wockhardt's share price go up? This page does not forecast Wockhardt Ltd's share price. What it shows instead: the share price is ₹1,899.00, and it has been rising for 24 weeks. Its P/E of 77.4× is higher than 32% of its own last 11 years (as of 4 November 2026). ### Who owns Wockhardt? Promoters own 49.3% of Wockhardt Ltd, foreign institutions 7.0%, domestic institutions 9.0% and the public 34.6% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 3.9 percentage points over 8 quarters (as of 4 November 2026). ### Does Wockhardt have too much debt? Wockhardt Ltd has a moderate amount of debt: its debt is 0.45× its equity, and its operating profit is 3 times its interest bill. FY26 borrowings were ₹2,233 Cr against equity of ₹4,940 Cr. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### Where is Wockhardt in its business cycle? Wockhardt Ltd's FY26 operating margin was 19.0%, against a 13-year range of −2.3% to 21.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 21.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Wockhardt story? The main question: profits are rising, but only 5% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Wockhardt a stock worth studying right now? What the numbers show: Wockhardt Ltd's results are improving, while its P/E is near the low end of its own history over 11 years, higher than only 32% of past readings. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Wockhardt share price forecast for 2026? What management itself guided: Zaynic launch in India within current fiscal year. What is changing at Wockhardt, from the latest results and calls: zaynic (wck-5222), fda approved, us commercial launch underway, biosimilar platform, 27% growth + capacity doubling and miqnaf + emrok, novel antibiotic base revenue. What would change the story: Cash conversion cycle expanded 108 days from FY22 to FY26; primary driver is payables compression (from 265 to 182 days); inventory days also rising to 286 days, signals capacity build for biosimilar ramp. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.